Literature DB >> 32145864

Canadian Cardiovascular Society Position Statement on Postural Orthostatic Tachycardia Syndrome (POTS) and Related Disorders of Chronic Orthostatic Intolerance.

Satish R Raj1, Juan C Guzman2, Paula Harvey3, Lawrence Richer4, Ronald Schondorf5, Colette Seifer6, Nicolas Thibodeau-Jarry7, Robert S Sheldon8.   

Abstract

The current definition of postural orthostatic tachycardia syndrome (POTS) dates back to a small case series of patients with a subacute illness who presented with excessive orthostatic tachycardia and orthostatic intolerance, in the absence of another recognized disease. Conventional POTS criteria require an excessive orthostatic tachycardia in the absence of substantial orthostatic hypotension, and predominant symptoms of orthostatic intolerance, worse with upright posture and better with recumbence. POTS is a heterogeneous syndrome with likely several underlying pathophysiological processes, and not a specific disease. The primary panel for this Canadian Cardiovascular Society position statement sought to provide a contemporary update of the best evidence for the evaluation and treatment of POTS. We performed a systemic review of evidence for the evaluation of treatment of POTS using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology, and developed recommendations on the basis of the Canadian Cardiovascular Society approach to position statements. One identified problem was that numerous patients who did not meet criteria for POTS would still be given that diagnoses by providers to validate the illness even though this diagnosis is incorrect. This includes patients with postural symptoms without tachycardia, orthostatic tachycardia without symptoms, and those with orthostatic tachycardia but another overt cause for excessive tachycardia. We developed a novel nomenclature ecosystem for orthostatic intolerance syndromes to increase clarity. We also provide more clarity on how to interpret the orthostatic vital signs. These concepts will need to be prospectively assessed.
Copyright © 2019 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2020        PMID: 32145864     DOI: 10.1016/j.cjca.2019.12.024

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  26 in total

1.  Pipedreams, the pandemic and PoTS: is the post-COVID-19 era a turning point for PoTS services?

Authors:  Morwenna Opie; Michaela Nuttall
Journal:  Br J Cardiol       Date:  2022-03-08

2.  Observational case series of postural tachycardia syndrome (PoTS) in post-COVID-19 patients.

Authors:  Nicholas P Gall; Stephen James; Lesley Kavi
Journal:  Br J Cardiol       Date:  2022-01-26

Review 3.  Sinus Tachycardia: a Multidisciplinary Expert Focused Review.

Authors:  Kenneth A Mayuga; Artur Fedorowski; Fabrizio Ricci; Rakesh Gopinathannair; Jonathan Walter Dukes; Christopher Gibbons; Peter Hanna; Dan Sorajja; Mina Chung; David Benditt; Robert Sheldon; Mirna B Ayache; Hiba AbouAssi; Kalyanam Shivkumar; Blair P Grubb; Mohamed H Hamdan; Stavros Stavrakis; Tamanna Singh; Jeffrey J Goldberger; James A S Muldowney; Mark Belham; David C Kem; Cem Akin; Barbara K Bruce; Nicole E Zahka; Qi Fu; Erik H Van Iterson; Satish R Raj; Fetnat Fouad-Tarazi; David S Goldstein; Julian Stewart; Brian Olshansky
Journal:  Circ Arrhythm Electrophysiol       Date:  2022-09-08

Review 4. 

Authors:  Satish R Raj; Artur Fedorowski; Robert S Sheldon
Journal:  CMAJ       Date:  2022-06-20       Impact factor: 16.859

5.  Effect of High Dietary Sodium Intake in Patients With Postural Tachycardia Syndrome.

Authors:  Emily M Garland; Alfredo Gamboa; Victor C Nwazue; Jorge E Celedonio; Sachin Y Paranjape; Bonnie K Black; Luis E Okamoto; Cyndya A Shibao; Italo Biaggioni; David Robertson; André Diedrich; William D Dupont; Satish R Raj
Journal:  J Am Coll Cardiol       Date:  2021-05-04       Impact factor: 24.094

6.  Patients With Postural Orthostatic Tachycardia Syndrome Have Different Experiences in Health Care in Canada and the United States.

Authors:  Juliette Hall; Kate M Bourne; Lauren E Stiles; Robert S Sheldon; Cyndya A Shibao; Luis E Okamoto; Emily M Garland; Alfredo C Gamboa; Andre Diedrich; Italo Biaggioni; David Robertson; Satish R Raj
Journal:  Can J Cardiol       Date:  2021-08-08       Impact factor: 6.614

7.  A comparison of health-related quality of life in autonomic disorders: postural tachycardia syndrome versus vasovagal syncope.

Authors:  Juliette Hall; Kate M Bourne; Robert S Sheldon; Steven Vernino; Vidya Raj; Jessica Ng; Luis E Okamoto; Amy C Arnold; Meredith Bryarly; Lauren Phillips; Sachin Y Paranjape; Satish R Raj
Journal:  Clin Auton Res       Date:  2021-02-07       Impact factor: 5.625

Review 8.  Dyspnea in Chronic Low Ventricular Preload States.

Authors:  Rubabin Tooba; Kenneth A Mayuga; Robert Wilson; Adriano R Tonelli
Journal:  Ann Am Thorac Soc       Date:  2021-04

9.  Postural orthostatic tachycardia syndrome (POTS): State of the science and clinical care from a 2019 National Institutes of Health Expert Consensus Meeting - Part 1.

Authors:  Steven Vernino; Kate M Bourne; Lauren E Stiles; Blair P Grubb; Artur Fedorowski; Julian M Stewart; Amy C Arnold; Laura A Pace; Jonas Axelsson; Jeffrey R Boris; Jeffrey P Moak; Brent P Goodman; Kamal R Chémali; Tae H Chung; David S Goldstein; Andre Diedrich; Mitchell G Miglis; Melissa M Cortez; Amanda J Miller; Roy Freeman; Italo Biaggioni; Peter C Rowe; Robert S Sheldon; Cyndya A Shibao; David M Systrom; Glen A Cook; Taylor A Doherty; Hasan I Abdallah; Anil Darbari; Satish R Raj
Journal:  Auton Neurosci       Date:  2021-06-05       Impact factor: 2.355

10.  High-sodium diet does not worsen endothelial function in female patients with postural tachycardia syndrome.

Authors:  Emily C Smith; Jorge Celedonio; Victor C Nwazue; Emily M Garland; Sachin Y Paranjape; Abby H Chopoorian; Amr Wahba; Italo Biaggioni; Bonnie Black; Cyndya A Shibao; André Diedrich; Luis E Okamoto; Satish R Raj; Alfredo Gamboa
Journal:  Clin Auton Res       Date:  2021-03-10       Impact factor: 5.625

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.